Skip to main content
Top
Published in: Annals of General Psychiatry 1/2020

Open Access 01-12-2020 | Schizophrenia | Primary research

The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey

Authors: Rajiv Tandon, William R. Lenderking, Catherine Weiss, Huda Shalhoub, Carla Dias Barbosa, Jun Chen, Mallik Greene, Stine R. Meehan, Laëtitia Bouérat Duvold, Celso Arango, Ofer Agid, David Castle

Published in: Annals of General Psychiatry | Issue 1/2020

Login to get access

Abstract

Background

It is well established that the different antipsychotics used for schizophrenia symptoms differ substantially in their side effects. However, relatively little is known about the impact of these side effects on functioning from the patient’s perspective. We aimed to understand how key side effects of second-generation antipsychotics impact the functioning and quality of life (QoL) of patients with schizophrenia.

Methods

This is a cross-sectional, web-based survey of patient-reported side effect burden of antipsychotic drugs in adults with schizophrenia. The survey was deployed in the United States, Canada, Australia, Spain, Italy, Norway, and Denmark. It included sociodemographic and clinical questions, the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF), and the Glasgow Antipsychotic Side-Effect Scale (GASS). Eight pre-defined key side effects classified as activating (“Shaky hands or arms,” “Restlessness,” and “Difficulty sleeping”), sedating (“Sleepy during the day”, “Feeling drugged or like a zombie,” and “Feeling dizzy/Fainted”) or other side effects (“Problems enjoying sex” and “Gaining weight”), and additional questions related to impacts on function and quality of life were asked.

Results

In total, 435 participants (mean age: 38 years, 53.8% female) were included. The total Q-LES-Q-SF score indicated overall medium satisfaction with their quality of life (score of 44.3; possible range 14–70). The most prevalent side effects were “Sleepy during the day” (83.2%), “Difficulty sleeping” (74.7%), “Dry mouth” (63.9%), “Problems enjoying sex” (53.4%) and “Gaining weight” (52.4%). Women reported the side effects of “Sleepy during the day”, “Problems enjoying sex” and “Gaining weight” more frequently than men. Key side effects impacted physical, social, occupational and psychological aspects of functioning. Patients with key side effects often felt frustrated by their experiences. Total Q-LES-Q-SF score showed a significant inverse correlation with the score of pre-defined groups of side effects indicating worse QoL in association with more severe key side effects in these patients.

Conclusion

Stable patients with schizophrenia taking second-generation antipsychotics live with many side effects, including activating and sedating side effects, sexual side effects, and weight gain. Presence of these side effects is associated with substantial impacts across all aspects of daily functioning and lower quality of life and satisfaction.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169–79.PubMedCrossRef Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169–79.PubMedCrossRef
2.
go back to reference Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatr. 2014;11:3–7.PubMedCrossRef Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatr. 2014;11:3–7.PubMedCrossRef
3.
go back to reference Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20.PubMedPubMedCentralCrossRef Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20.PubMedPubMedCentralCrossRef
4.
go back to reference Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.PubMedCrossRef Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.PubMedCrossRef
5.
go back to reference Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry. 2002;17(3):129–38.PubMedCrossRef Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry. 2002;17(3):129–38.PubMedCrossRef
6.
go back to reference Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007;93(1–3):90–8.PubMedPubMedCentralCrossRef Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007;93(1–3):90–8.PubMedPubMedCentralCrossRef
7.
go back to reference Bains S, Shah AA. Sexual side effects of antipsychotic drugs. Pharmacoepidem Drug Saf. 2012;1:109. Bains S, Shah AA. Sexual side effects of antipsychotic drugs. Pharmacoepidem Drug Saf. 2012;1:109.
8.
go back to reference Morgan V, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, et al. People Living with Psychotic Illness 2010. Report on the Second Australian National Survey. Commonwealth of Australia. 2011 Morgan V, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, et al. People Living with Psychotic Illness 2010. Report on the Second Australian National Survey. Commonwealth of Australia. 2011
9.
go back to reference Usher K, Park T, Foster K. The experience of weight gain as a result of taking second-generation antipsychotic medications: the mental health consumer perspective. J Psychiatr Ment Health Nurs. 2013;20(9):801–6.PubMed Usher K, Park T, Foster K. The experience of weight gain as a result of taking second-generation antipsychotic medications: the mental health consumer perspective. J Psychiatr Ment Health Nurs. 2013;20(9):801–6.PubMed
10.
go back to reference Tandon R, Halbreich U. The second-generation ‘atypical’ antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology. 2003;28(Suppl 1):1–7.PubMedCrossRef Tandon R, Halbreich U. The second-generation ‘atypical’ antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology. 2003;28(Suppl 1):1–7.PubMedCrossRef
11.
go back to reference Carey TA. Beyond patient-centered care: enhancing the patient experience in mental health services through patient-perspective care. Patient Exp J. 2016;3(2):46–9.CrossRef Carey TA. Beyond patient-centered care: enhancing the patient experience in mental health services through patient-perspective care. Patient Exp J. 2016;3(2):46–9.CrossRef
12.
go back to reference Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008;22(3):238–43.PubMedCrossRef Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008;22(3):238–43.PubMedCrossRef
13.
go back to reference Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–6.PubMed Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–6.PubMed
14.
go back to reference Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35(5):937–48.PubMedCrossRef Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35(5):937–48.PubMedCrossRef
15.
go back to reference Seeman MV. Men and women respond differently to antipsychotic drugs. Neuropharmacology. 2020;163:107631.PubMedCrossRef Seeman MV. Men and women respond differently to antipsychotic drugs. Neuropharmacology. 2020;163:107631.PubMedCrossRef
16.
go back to reference Young SL, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29(4):353–62.PubMedCrossRef Young SL, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29(4):353–62.PubMedCrossRef
17.
go back to reference Iversen TSJ, Steen NE, Dieset I, Hope S, Morch R, Gardsjord ES, et al. Side effect burden of antipsychotic drugs in real life—impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263–71.PubMedCrossRef Iversen TSJ, Steen NE, Dieset I, Hope S, Morch R, Gardsjord ES, et al. Side effect burden of antipsychotic drugs in real life—impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263–71.PubMedCrossRef
18.
go back to reference Lysaker PH, Salyers MP. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand. 2007;116(4):290–8.PubMedCrossRef Lysaker PH, Salyers MP. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand. 2007;116(4):290–8.PubMedCrossRef
19.
20.
go back to reference Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535–40.PubMedCrossRef Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535–40.PubMedCrossRef
22.
go back to reference Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry. 1997;154(1):99–105.PubMedCrossRef Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry. 1997;154(1):99–105.PubMedCrossRef
Metadata
Title
The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
Authors
Rajiv Tandon
William R. Lenderking
Catherine Weiss
Huda Shalhoub
Carla Dias Barbosa
Jun Chen
Mallik Greene
Stine R. Meehan
Laëtitia Bouérat Duvold
Celso Arango
Ofer Agid
David Castle
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2020
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/s12991-020-00292-5

Other articles of this Issue 1/2020

Annals of General Psychiatry 1/2020 Go to the issue